Alterity Therapeutics Ltd. · ASX:ATH
Alterity Therapeutics — Investor Presentation (December 2020)
12 slides from Alterity Therapeutics's investor presentation, December 2020
Slide 1: Alterity Therapeutics
Alterity Therapeutics (NASDAQ:ATHE, ASX:ATH) Geoffrey Kempler, CEO and Chairman December 2020 CONFIDENTIAL 1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain some statements that may be considered “Forward-Looking Statements”, within the meaning of the US Securities Laws. Thus, any forward-looking statement relating to financial projections or other statements relating to the Company’s plans, objec
Slide 3: Our Purpose
Our Purpose We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory for people with these diseases. CONFIDENTIAL 3
Slide 4: Year in Review
Year in Review Allowance of US patent for next ATH434 crosses blood brain barrier in generation compounds to treat humans; clinically tested doses achieved neurodegenerative diseases concentrations in the brain Raises $35M in placement to European Commission approves Orphan international and Austral
Slide 5: Parkinsonian Disorders − A Significant Unmet Need
Parkinsonian Disorders − A Significant Unmet Need Parkinsonism is a syndrome of motor symptoms that includes slowness of movement, stiffness and tremor Major source of disability Parkinsonian disorders also include MSA atypical variants such as Multiple system atrophy (MSA) and Parkinson’s Pro
Slide 6: Excellent Progress with Lead Drug Candidate ATH434
Excellent Progress with Lead Drug Candidate ATH434 Robust efficacy in animal Completed Phase 1 Qualitative research with models of disease Orally bioavailable, brain penetrant U.S. neurologists completed Evidence of neuroprotection with ATH434: safe and well tolerated 15 movement disor
Slide 7: bioMUSE Natural History Study
bioMUSE Natural History Study • Design: Observational (no treatment) • Objective: De-risk Phase 2 study • Identify biomarker(s) suitable for endpoint in treatment study • Evaluate the change in biomarkers and clinical manifestations in patients with early MSA to track disease progression • Populatio
Slide 8: Phase 2 Study Design
Phase 2 Study Design • Design: Randomized, double-blind, placebo controlled • Objectives • Assess target engagement and preliminary efficacy of ATH434 • Evaluate safety and tolerability of ATH434 • Population: Early MSA patients (parkinsonian variant) with motor symptoms ≤ 3 years • Sample size: 60
Slide 9: Commercial Opportunity – Multiple System Atrophy
Commercial Opportunity – Multiple System Atrophy Independent Analysis STRONG INTENT TO SUBSTANTIAL UNMET NEED PRESCRIBE Severely debilitating, fatal illnesses with Motivated by efficacy in treating the no current treatments are ripe for new underlying disease and not just the entrants targeting what
Slide 10: Leadership of 3 FDA Approvals in Neurology
Leadership of 3 FDA Approvals in Neurology David Stamler, M.D. Chief Medical Officer FDA Advisory Committee Votes Unanimously to Recommend Approval of Tetrabenazine for Chorea Associated With Huntington • 3 FDA Approvals in Neurology Disease • Led FDA Advisory Committee and approval of Dec 7, 2007 X
Slide 11: Investment Summary
Investment Summary Targeting Orphan disease with no approved treatments • ATH434 has potential U.S. peak sales up to US$ 725 million Development team with proven track record at FDA Lead drug candidate ATH434 • Commenced natural history study to inform Phase 2 study • Completed Phase 1 with ex
Slide 12: For further information please contact
For further information please contact: [email protected]
Alterity Therapeutics — Investor Presentation (December 2020) on 6ix